OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinica
- Corax Consultants LLC
- 11. Apr. 2024
- 1 Min. Lesezeit
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
Kommentare